About: Blood pressure control and adverse outcomes of COVID-19 infection in patients with concomitant hypertension in Wuhan, China

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Blood pressure control and adverse outcomes of COVID-19 infection in patients with concomitant hypertension in Wuhan, China Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Blood pressure control and adverse outcomes of COVID-19 infection in patients with concomitant hypertension in Wuhan, China
Creator	Yang, Lin Song, Ying Cao, Peihua Ran, Jinjun Zhuang, Zian Qin, Jing Shi, • Wu, • Xu, • Geng, Yan Daihai He, • Lefei, •
topic	covid:33a4ddd242c758b21641c30c92f99a0c5fd81fc1#this
source	Medline; PMC
abstract	Hypertension is a common comorbidity in hospitalized patients with COVID-19 infection. This study aimed to estimate the risks of adverse events associated with in-hospital blood pressure (BP) control and the effects of angiotensin II receptor blocker (ARB) prescription in COVID-19 patients with concomitant hypertension. In this retrospective cohort study, the anonymized medical records of COVID-19 patients were retrieved from an acute field hospital in Wuhan, China. Clinical data, drug prescriptions, and laboratory investigations were collected for individual patients with diagnosed hypertension on admission. Cox proportional hazards models were used to estimate the risks of adverse outcomes associated with BP control during the hospital stay. Of 803 hypertensive patients, 67 (8.3%) were admitted to the ICU, 30 (3.7%) had respiratory failure, 26 (3.2%) had heart failure, and 35 (4.8%) died. After adjustment for confounders, the significant predictors of heart failure were average systolic blood pressure (SBP) (hazard ratio (HR) per 10 mmHg 1.89, 95% confidence interval (CI): 1.15, 3.13) and pulse pressure (HR per 10 mmHg 2.71, 95% CI: 1.39, 5.29). The standard deviations of SBP and diastolic BP were independently associated with mortality and ICU admission. The risk estimates of poor BP control were comparable between patients receiving ARBs and those not receiving ARBs, with the only exception of a high risk of heart failure in the non-ARB group. Poor BP control was independently associated with higher risks of adverse outcomes of COVID-19. ARB drugs did not increase the risks of adverse events in hypertensive patients.
has issue date	2020-08-27(xsd:dateTime)
bibo:doi	10.1038/s41440-020-00541-w
bibo:pmid	32855527
has license	no-cc
sha1sum (hex)	33a4ddd242c758b21641c30c92f99a0c5fd81fc1
schema:url	https://doi.org/10.1038/s41440-020-00541-w
resource representing a document's title	Blood pressure control and adverse outcomes of COVID-19 infection in patients with concomitant hypertension in Wuhan, China
has PubMed Central identifier	PMC7450040
has PubMed identifier	32855527
schema:publication	Hypertens Res
resource representing a document's body	covid:33a4ddd242c758b21641c30c92f99a0c5fd81fc1#body_text
is http://vocab.deri.ie/void#inDataset of	https://covidontheweb.inria.fr:4443/about/id/http/ns.inria.fr/covid19/33a4ddd242c758b21641c30c92f99a0c5fd81fc1
is schema:about of	named entity 'outcomes' named entity 'died' named entity 'mortality' named entity 'COVID-19' named entity 'risks' named entity 'independently' named entity 'Cox proportional hazards' named entity 'adverse' named entity 'blood pressure' named entity 'patients' named entity 'adverse' named entity 'MORTALITY' named entity '1.39' named entity 'RISKS' named entity 'ASSOCIATED WITH' named entity 'SBP' named entity 'estimate' named entity 'mmHg' named entity 'COVID-19' named entity 'patients' named entity 'This' named entity 'risks' named entity 'Clinical' named entity 'adverse events' named entity 'respiratory failure' named entity 'risks' named entity 'investigations' named entity 'anonymized' named entity 'acute' named entity 'comorbidity' named entity 'high risk' named entity 'collected' named entity 'ARB' named entity 'outcomes' named entity 'individual' named entity 'ICU' named entity 'medical records' named entity 'estimates' named entity 'hypertensive' named entity 'Hypertension' named entity 'mmHg' named entity 'pulse pressure' named entity 'drug prescriptions' named entity 'mmHg' named entity 'diastolic' named entity 'COVID' named entity 'laboratory investigations' named entity 'blood pressure' named entity 'comorbidity' named entity 'ICU' named entity 'Blood pressure' named entity 'arterial partial pressure of carbon dioxide' named entity 'heart diseases' named entity 'ICU' named entity 'COVID-19' named entity 'long-term' named entity 'Hypertension' named entity 'blood pressure' named entity 'ACE inhibitors' named entity 'systolic blood pressure' named entity 'China' named entity 'fatigue' named entity 'pneumonia' named entity 'Dose-response curves' named entity 'hypertension' named entity 'Mann-Whitney' named entity 'ICU' named entity 'virus entry'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software